Table 1.
Elesclomol-related clinical trials
| Clinical Trial Subjects | Staging of Clinical Trials | Recruitment Status | Drug use | Results | References |
|---|---|---|---|---|---|
| Acute myeloid leukemia | Phase I | Unknown | Elesclomol sodium | Elesclomol has a good clinical safety profile, but patients have not developed clinical responses to elesclomol | 26732437 |
| Solid tumors | Phase I | Completed | Elesclomol sodium, Paclitaxel | The combination of Elesclomol and paclitaxel was well tolerated by patients and the toxicity profile of elesclomol was similar to that of single agent paclitaxel | 17255281 |
| Melanoma | Phase I/II | Completed | Elesclomol sodium, Paclitaxel | The combination of elesclomol and paclitaxel resulted in a statistically significant doubling of median PFS, with an acceptable toxicity profile and encouraging OS | 19826135 |
| Melanoma | Phase III | Terminated | Elesclomol sodium, Paclitaxel | The combination of elesclomol and paclitaxel did not significantly improve PFS | 23401447 |
| Recurrent or persistent ovarian epithelial cancer, fallopian tube cancer, primary peritoneal cancer | Phase II | Completed | Elesclomol sodium, Paclitaxel | The combination of elesclomol and paclitaxel was well tolerated by patients but the proportion responding was low | 30309721 |
| Solid tumors | Phase I | Suspended | Elesclomol sodium | Unpublished | - |
| Prostate cancer | Phase I | Completed | Elesclomol sodium, Docetaxel | Unpublished | - |
| Stage IIIB/IV non-small cell lung cancer | Phase I/II | Completed | Elesclomol sodiuml, Paclitaxel, Carboplatin | Unpublished | - |
| Soft tissue sarcoma | Phase II | Completed | Elesclomol sodium, taxane | Elesclomol enhanced taxane efficacy by induction of Hsp70 | 16784029 |
Elesclomol-related clinical trials were searched using the ClinicalTrials.gov platform. Nearly a dozen clinical trials related to elesclomol treatment have been conducted with the estimated enrollment of a thousand patients with different types of cancers, including melanoma, ovarian cancer, and acute myeloid leukemia. Unfortunately, according to published results, the clinical anticancer efficacy of elesclomol is suboptimal, but patients have good tolerance to elesclomol
PFS Progression-free survival, OS Overall survival